ArticleJournal of translational autoimmunity2021
Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19.
Article in Journal of translational autoimmunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 6 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Prevalence of autoantibody responses in COVID-19 patients: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Thyroid disorders and COVID-19: a comprehensive review of literature.Frontiers in endocrinology · 2025Pooled it
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- Prevalence of comorbid tuberculosis amongst COVID-19 patients: A rapid review and meta-analysis.International journal of clinical practice · 2021Pooled it
- Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?Current rheumatology reports · 2021Pooled it
- Systematic review of COVID-19 and autoimmune thyroiditis.Travel medicine and infectious diseasePooled it
- Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.BMC infectious diseases · 2022Trial
- The long-lived immune system of centenarians.Nature reviews. Immunology · 2026Review
- Xenosialylation as immunological chimerism: a host-centered unifying model for viral and post-vaccination immune complications.European cytokine network · 2026Review
- Exploring the immunomodulatory effects of environmental contaminants on autoimmune patients: AnJournal of translational autoimmunity · 2026Article
- NET Biomarkers in COVID-19 and Post-COVID Syndrome: a Comprehensive Analysis.Journal of clinical immunology · 2026Article
- COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy.Clinical reviews in allergy & immunology · 2025Review
- Study on the dynamic changes in antinuclear antibody spectrum in SARS-CoV-2 infection: a retrospective analysis.BMC infectious diseases · 2025Article
- Association between mental health symptoms and autoimmunity in patients with long COVID.BMC infectious diseases · 2025Observational
- NETosis: A key player in autoimmunity, COVID-19, and long COVID.Journal of translational autoimmunity · 2025Review
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Rheumatoid arthritis-associated rheumatoid factors post-COVID-19.Frontiers in immunology · 2025Article
- Autoantibodies in long COVID in a black/mixed population compared with recovered and pre-pandemic controls.Frontiers in immunology · 2025Article
- Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19.Nature communications · 2024Article
- Autoimmunity in centenarians. A paradox.Journal of translational autoimmunity · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune responses mediated by autoantibodies have been observed in SARS-CoV-2 infection. Herein, we evaluate the presence of rheumatic, thyroid and phospholipid autoantibodies in sera samples from 120 adult hospitalized patients with COVID-19 in comparison to pre-pandemic samples from 100 healthy individuals. In addition, to estimate the frequency of these autoantibodies in COVID-19, a meta-analysis of selected articles was conducted. Hospitalized patients with COVID-19 had latent autoimmunity characterized by a high frequency of anti-thyroid peroxidase antibodies, rheumatoid factor (RF), anti-cyclic citrullinated peptide third generation antibodies, antinuclear antibodies (ANAs), IgM anti-β2-glycoprotein I (β2GP1) and IgM anti-cardiolipin antibodies. The meta-analysis confirmed our results, with RF and ANAs being the most common autoantibodies. In addition, cluster analysis revealed that those patients with high frequency of RF, IgM anti-β2GP1 antibodies and ANAs had a longer hospital stay, required more vasopressors during hospitalization, and were more likely to develop critical disease. These data suggest that latent autoimmunity influences the severity of COVID-19, and support further post-COVID studies in order to evaluate the development of overt autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.